Founded in Honolulu, United States, Cardax, Inc. is dedicated to developing and marketing pharmaceutical therapies that address inflammation using naturally occurring compounds. The company's core mission is to provide safe and effective anti-inflammatory treatments, with a particular focus on astaxanthin, a compound known for its inflammation-reducing properties. Cardax's primary product, ZanthoSyn®, is a dietary supplement recommended by physicians for inflammatory health.
Cardax has attracted notable investors and industry experts who support its innovative approach to anti-inflammatory treatments. The company has achieved significant milestones, including the successful commercialization of ZanthoSyn® and the development of a proprietary platform for small molecule compounds targeting oxidative stress and inflammation. Cardax's impact lies in its commitment to addressing large unmet medical needs with safe, natural solutions, thereby improving consumer health and reducing corporate costs.
